Oncogenic translation directs spliceosome dynamics revealing an integral role for SF3A3 in breast cancer.
DRP1
MYC
SF3A3
alternative splicing
cancer plasticity
cancer stem cells
eIF3D
mitochondrial dynamics
translation control
triple-negative breast cancer
Journal
Molecular cell
ISSN: 1097-4164
Titre abrégé: Mol Cell
Pays: United States
ID NLM: 9802571
Informations de publication
Date de publication:
01 04 2021
01 04 2021
Historique:
received:
07
07
2020
revised:
02
12
2020
accepted:
21
01
2021
pubmed:
5
3
2021
medline:
15
4
2021
entrez:
4
3
2021
Statut:
ppublish
Résumé
Splicing is a central RNA-based process commonly altered in human cancers; however, how spliceosomal components are co-opted during tumorigenesis remains poorly defined. Here we unravel the core splice factor SF3A3 at the nexus of a translation-based program that rewires splicing during malignant transformation. Upon MYC hyperactivation, SF3A3 levels are modulated translationally through an RNA stem-loop in an eIF3D-dependent manner. This ensures accurate splicing of mRNAs enriched for mitochondrial regulators. Altered SF3A3 translation leads to metabolic reprogramming and stem-like properties that fuel MYC tumorigenic potential in vivo. Our analysis reveals that SF3A3 protein levels predict molecular and phenotypic features of aggressive human breast cancers. These findings unveil a post-transcriptional interplay between splicing and translation that governs critical facets of MYC-driven oncogenesis.
Identifiants
pubmed: 33662273
pii: S1097-2765(21)00054-X
doi: 10.1016/j.molcel.2021.01.034
pii:
doi:
Substances chimiques
MYC protein, human
0
Proto-Oncogene Proteins c-myc
0
RNA Splicing Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1453-1468.e12Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests A.B. received travel grants from Roche and participated in advisory board meetings for Pfizer and Novartis. All other authors declare no competing interests.